DC-SIGN as a novel Fc receptor: relationship with structure, function and immunogenicity of therapeutic antibodies
| Project/Area Number |
23590214
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | National Institute of Health Sciences |
|---|
Principal Investigator |
ISHII Akiko 国立医薬品食品衛生研究所, 生物薬品部, 室長 (50291117)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TADA Minoru 国立医薬品食品衛生研究所, 生物薬品部・第三室, 室長 (50506954)
SUZUKI Takuo 国立医薬品食品衛生研究所, 生物薬品部・第一室, 主任研究官 (10415466)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | DC-SIGN / 抗体医薬品 / Fc受容体 |
|---|
| Outline of Final Research Achievements |
The purpose of this study was to elucidate the role of DC-SIGN, whose involvement in anti-inflammatory action of intravenous immunoglobulin was reported, in structure and function of therapeutic antibodies. SNA-lectin absorbed fraction purified from intravenous immunoglobulin or recombinant IgG prepared by co-transfection of the plasmids encoding IgG and sialyl transferase were used as sialylated IgG. Binding assay using DC-SIGN expressing cells and Surface plasmon resonance spectroscopy were performed. However, binding between sialylated IgG and DC-SIGN was not observed. Other mechanism than direct binding between DC-SIGN and sialylated IgG may be involved in the anti-inflammatory action of therapeutic IVIG.
|
Report
(5 results)
Research Products
(7 results)
